• Vive Summary Vive reformulates existing pesticides for the $46 Billion crop protection industry, addressing issues jeopardizing the industry • • Replace organic solvents with biodegradable or bio-inert polymers Working with six global crop protection companies on products with $8 billion total addressable market • • • Six products in field trials with results expected by year end Trials demonstrate Vive formulations are more effective than current products Products and process are patented and are 100% owned • Experienced management team and advisors • Raised $16 MM to date 2

The Growing Use of Pesticides is Assured $ 46B

pesticide industry

• • • • Crop Yields are a Worldwide Issue Population growth Shrinking arable land Changing diets Biofuels 3

Yet Industry Profits are Under Pressure

Patent Cliff Lack of New Molecules Regulatory Barriers

Crop Protection Industry

Syngenta | Bayer | BASF | DuPont | Dow

Pressure from Generics

4

Addressing Crop Protection Industry’s Key Issues

Patentable

• New IP without new active ingredient

Products Competitive

• • • • Economics Efficacy Convenience Grower safety

Approvable

• • Avoid toxic formulations Environmental safety 5

Vive Patented Technology Platform

IP Generating Innovative

• • Broadly applicable reformulation technology Lower development cost per product • • Improves economics, efficacy, safety, convenience Fast timelines

Approvable

• • Improves handling and safety Enables water to act as the only solvent 6

Vive Technology Active Ingredient (AI) Vive Cage Vive New Product Not soluble in water Encapsulates AI in a water dispersible (non-toxic) structure Encapsulated AI dispersed in water

Vive Technology Platform Water and bio-inert polymers create a cage that delivers the active ingredient 8

Simple, Scalable Manufacturing • Low capital cost — uses off the shelf equipment • Main inputs are EPA approved polymers • Straightforward path to large commercial scale • $4 MM capex for 200T Allosperse plant Pilot Scale Plant (Five tonnes per year)

Low Capex with Significant Product Leverage

Vive 200 Tonne plant 600 Tonnes of partner supplied active ingredient

6,000 Tonnes of packaged product with >$100 MM in annual revenue

10

Four Levels of IP Protection

Product IP Patent Cliff Application IP Process IP • 12 issued patents (first expiry 2017) • 52 patents pending • 7 families in the US and internationally • New products via patentable reformulations • First reformulated product patents to be filed in 2012 Composition of Matter IP

Ongoing IP Generation

11

Vive Product Portfolio

Patented Actives

• Developing products with branded companies • $5 Billion+ addressable market • Upfront, milestone and royalty revenue

Generic Actives

• Developing products to be distributed through branded companies • $3 Billion+ addressable market • Product revenue

Portfolio Renewal and Extension Model

12

Improved Insecticide Efficacy • • • • Third party trials tested Vive’s formulated cypermethrin versus the leading competitive

Partnered Product

Both products were applied at 0.1ppm

Tests demonstrated superior performance killing pests and protecting plants Results have been confirmed in 5 different trials

Treatment

Vive Ammo

Pests Killed

90% 5%

Plant Damage

(Lower is Better)

1.1% 32.5%

Vive’s formulation was 18x more effective killing pests and ~30x more effective protecting plants from insect damage

What Does it Mean to the Farmer?

• •

Potential product benefits include:

Better plant protection – higher yields Buy and use less pesticide – save money 13

Improved Residual Activity • • • Trials test how long a product keeps working after it is applied • Third party trials tested Vive’s formulated

Partnered Product

product, Syngenta’s Karate Zeon, at identical concentrations Karate Zeon is marketed against “standard” products based on its superior residual activity Results show that Vive’s formulation is better after 7 and 14 days

Treatment

Vive

Pests Killed 7 Days Later

90% What Does it Mean to the Farmer?

Pests Killed 14 Days Later

76% Karate Zeon 50% 42%

Vive’s formulation was 80% more effective killing pests both one and two weeks after application

• •

Potential product benefits include:

Sustained protection – higher yields, better crops Apply less often – save money and hassle 14

Potential Markets

Crop Protection TAM => $50 Bn Beauty and Personal Care TAM => $425 Bn Nutritionals TAM => $100 Bn Industrial TAM => $300 Bn Pharmaceuticals TAM => $500 Bn

Potential Markets > $1 Trillion

15

Corporate Information

16

Management

Keith Thomas

CEO

Darren Anderson

CTO

Flavio Campagnaro

VP Manufacturing

Skip Campbell

VP Product Creation

Ken Yoon

CFO and VP Corp Development Entrepreneur, project management and corporate finance; Booz Allen, Citigroup, BASc (Toronto), MA (Toronto), MBA (Columbia) Founding president, 4 issued patents, 24 pending applications, 10 refereed papers, over 40 conference presentations and publications, PhD (Toronto) Senior process engineer, scaled large environmental plants; Bennett Environmental, BASc (UBC), PEng Boston-based M&A and advisory for high-tech industries, consulting and VC experience, BA (Williams), MBA (Toronto) Life sciences venture capitalist, consulting and accounting; VenGrowth, Ernst & Young, BSc (Western), LLB (Queen’s), MBA (Toronto), CA Supplemented by 10 advisors with experience at Syngenta, BASF, DuPont, Dow, FMC ,etc.

17

Directors

Neil Reid

Chair

Charlie Fischer

Director

Warren Libby

Director

Bill Lambert

Director

Mark MacDonald

Director Co-founder, MDS Sciex Former CEO, Dow AgroSciences; Former Chair, CropLife America and CropLife International Former President, Syngenta Canada; Former Chairman, Crop Protection Institute of Canada Chairman, Ag Growth International; Former Partner, TD Capital Former VP, Teachers Private Equity; significant board experience

The Vive Opportunity  $46 Billion global market opportunity with assured demand with significant potential in additional markets  Patent cliff, formulation issues and generics are unavoidable  Disruptive, patented, green technology addresses industry needs  Products with $8 Billion addressable market in dev and trials  Strong management team and directors  Commercial deals in 2013 and product launches in 2014 19